NewsRoom Articles - Page 122 of 225

WednesdayJun 01, 2022 2:35 pm

Exposure to Wildfires Amplifies Cancer Risk, New Study Finds

Wildfires usually occur in every year in similar areas, with those who live near these regions being exposed to carcinogenic pollutants on a long-term basis. Now new research has discovered a higher incidence of brain tumors and lung cancer in individuals who have been exposed to wildfires. The research, which was conducted by scientists from McGill University, tracked more than two million Canadians over a period of 20 years. It is the first study to assess how forest fire proximity may influence the risk of cancer. The researchers’ objective was to characterize the relationship between the incidence of several cancer…

TuesdayMay 31, 2022 2:53 pm

How Your Mental Health May Benefit from a Digital Detox

In today’s world, we spend most of our day in front of a screen, be it a phone, laptop or computer. While what we’re doing may be productive, overusing technology may have a negative effect on mental health. This is why undergoing a digital and/or social detox to help disconnect from technology may be beneficial. Here’s what you need to know about media detoxes. What are social media and digital detoxes, and why should you detox? A social media detox is when an individual refrains from using or engaging with social media for a set period, or indefinitely, to improve…

TuesdayMay 31, 2022 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long,…

TuesdayMay 31, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical…

TuesdayMay 31, 2022 9:00 am

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking…

FridayMay 27, 2022 11:58 am

Study Suggests COVID-19 Increases Parkinson’s Disease Risk

New research has found that the virus known to cause COVID-19 may heighten the risk of brain degeneration observed in patients with Parkinson’s disease. For their study, the researchers used genetically engineered mice that could express the human ACE-2 receptor. It is this receptor that the SARS-CoV-2 virus uses to access the cells found in human airways. The researchers infected the mice with a SARS-CoV-2 dose that corresponded to a moderate coronavirus infection in people and then allowed them to recover. Of the total number of mice that were infected with the virus, 80% survived. After the mice had been…

ThursdayMay 26, 2022 1:02 pm

UNICEF Sounds the Alarm on the Worldwide Child Malnutrition Risk

UNICEF recently warned that the worldwide risk for child malnutrition, which was already increasing before Russia invaded Ukraine, had significantly risen. In its recent press release, UNICEF noted that 10% of children in Cambodia were actively impacted by malnutrition. The organization stated that severe wasting, which could be observed when a child was too thin for their height, is the most life threatening and visible form of malnutrition. In its Child Alert press release, the United Nations Children’s Fund estimated that globally, at least 13.5 million children aged five and below suffered from severe wasting. The press release added that…

ThursdayMay 26, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports efforts made by Cybin (NEO: CYBN) (NYSE American: CYBN), which is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.…

WednesdayMay 25, 2022 2:40 pm

New Research Outlines Autoimmune Hepatitis Risk Factors after Liver Transplantation

Data from the National Organization for Rare Disorders shows that roughly one to two individuals out of every 100,000 globally are diagnosed with autoimmune hepatitis annually. This rare liver disorder is characterized by an autoimmune response against healthy cells in the liver, which leads to cirrhosis, liver failure and eventually, death. Some patients with this disorder undergo liver transplants to treat the illness when it’s in its advanced stages. However, in some cases, the disease recurs, and not much has been known about what factors heightened the possibility of the disease recurring — until now. New research has outlined some risk…

TuesdayMay 24, 2022 11:53 am

Genomic Sequencing Offers Hope in Diagnosis, Treatment of Brain Tumors

New research has found that genomic profiling may play a key role in the diagnosis and grading of brain tumors. More accurate and new diagnoses can be generated from genomic profiling. Here, alterations in the DNA that drive the growth of tumors are identified. Previously, diagnosis was determined using microscopic comparisons between normal cells and cancer cells. This research was carried out by scientists at the University of California-San Francisco, who followed 38 patients with glioblastoma, IDL-wild type tumors. This type of tumor was recategorized from a grade 2/3 glioma to a central nervous system grade 4 tumor. The researchers…